Paying for statins

British Medical Journal

Volumn 328, Issue 7436, 2004, Pages 400-402

  Raithatha, Nick ^a   Smith, Richard D ^a  

^a UNIVERSITY OF EAST ANGLIA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; STATIN;

CARDIOVASCULAR DISEASE; CONGENITAL HEART DISEASE; CORONARY ARTERY DISEASE; COST; COST EFFECTIVENESS ANALYSIS; DISEASE COURSE; ECONOMICS; FEE; GENERAL PRACTICE; GENERAL PRACTITIONER; HEALTH CARE; HUMAN; MEDICAL EDUCATION; MEDICAL ETHICS; PATIENT MONITORING; PRESCRIPTION; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; PRIVATE PRACTICE; REVIEW; RISK FACTOR; SOCIETY; UNITED KINGDOM;

EID: 1242318668     PISSN: 09598146     EISSN: None     Source Type: Journal    
DOI: 10.1136/bmj.328.7436.400     Document Type: Review

References (18)

1. Department of Health. National service framework for coronary heart disease. London: Stationery Office, 2000.
2. Department of Health. Saving lives: our healthier nation. London: Stationery Office, 1999.
3. Jackson R. Guidelines on preventing cardiovascular disease in clinical practice. BMJ 2000;320:659-61.
4. Pignone M, Phillips C, Mulrow C. Use of lipid lowering drugs for primary prevention of coronary heart disease: meta-analysis of randomised trials. BMJ 2000;321:983-6.
5. Law MR, Wald NJ, Rudnicka A. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ 2003;326:1423-7.
6. Hulley S, Grady DB, Browner WS. Statins: underused by those who would benefit. BMJ 2000;321:971-2.
7. British Cardiac Society, British Hyperlipidaemia Association, British Hypertension Society, British Diabetic Association. Joint British recommendations on prevention of coronary heart disease. Heart 1998;80(suppl 2):S1-29.
8. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of Air Force/Texas coronary atherosclerosis prevention study. JAMA 1998;279:1615-22.
9. Pickin DM, McCabe CJ, Ramsay LE, Payne N, Haq IU, Yeo, WW, et al. Cost effectiveness of HMG-CoA reductase inhibitor (statin) treatment related to the risk of coronary heart disease and cost of drug treatment. Heart 1999;82:325-32.
10. Timmins N. Drugs and the NHS's £30 000 question. Financial Times 2001 Aug 10.
11. Haq IU, Ramsay LE, Wallis EJ, Isles CG, Jackson PR. Population implication of lipid lowering for prevention of coronary heart disease: data from the 1995 Scottish health survey. Heart 2001;86:289-95.
12. British Medical Association, Royal Pharmaceutical Society of Great Britain. British national formulary. London: BMA, RPS, 2003:128, 194. (No 45.)
13. National Statistics. Census 2001. www.statistics.gov.uk/census2001/ demographic_uk.asp (accessed 5 Dec 2003).
14. NHS core principles 2000. www.nhs.uk/nhsguide/1_coreprinciples.htm (accessed 5 Dec 2003).
15. Beattie J, Covey J, Dolan P, Hopkins L, Jones-Lee M, Loomes G, Pidgeon N, et al. On the contingent valuation of safety and the safety of contingent valuation. Part I: caveat investigator. J Risk Uncertain 1998;17:5-26.
16. Marks D, Wonderling B, Thorogood, M, Lambert, H. Screening for hypercholesterolaemia versus case finding for familial hypercholesterolaemia: a systematic review and cost-effectiveness analysis. Health Technol Assess 2000;4(29):1-123.
17. Rawls J. A theory of justice. Oxford: Oxford University Press, 1972.
18. Department of Health. Fair for all, personal to you: choice, responsiveness and equity in the NHS and social care. London: Stationery Office, 2003.